Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients

Iva Truxova 1,2†, Lenka Kasikova 1,2†, Michal Hensler 2, Petr Skapa 3, Jan Laco 4, Ladislav Pecen 2, Lucie Belicova 2, Ivan Praznovec 5, Michael J. Halaska 6, Tomas Brtnicky 7, Eva Salkova 3, Lukas Rob 6, Roman Kodet 3, Jeremy Goc 8,9,10, Catherine Sautes-Fridman 8,9,10, Wolf Herman Fridman 8,9,10, Ales Ryska 6, Lorenzo Galluzzi 10,11,12, Radek Spisek 1,2 and Jitka Fucikova 1,2*

Abstract
A high density of tumor-infiltrating CD8+ T cells and CD20+ B cells correlates with prolonged survival in patients with a wide variety of human cancers, including high-grade serous ovarian carcinoma (HGSC). However, the potential impact of mature dendritic cells (DCs) in shaping the immune contexture of HGSC, their role in the establishment of T cell-dependent antitumor immunity, and their potential prognostic value for HGSC patients remain unclear. We harnessed immunohistochemical tests and biomolecular analyses to demonstrate that a high density of tumor-infiltrating DC-LAMP+ DCs is robustly associated with an immune contexture characterized by TH1 polarization and cytotoxic activity. We showed that both mature DCs and CD20+ B cells play a critical role in the generation of a clinically-favorable cytotoxic immune response in HGSC microenvironment. In line with this notion, robust tumor infiltration by both DC-LAMP+ DCs and CD20+ B cells was associated with most favorable overall survival in two independent cohorts of chemotherapy-naïve HGSC patients. Our findings suggest that the presence of mature, DC-LAMP+ DCs in the tumor microenvironment may represent a novel, powerful prognostic biomarker for HGSC patients that reflects the activation of clinically-relevant anticancer immunity.

Keywords: Dendritic cells, DC-LAMP, CD8+ cytotoxic T lymphocytes, Natural killer cells, Tertiary lymphoid structures

Introduction
Tumors emerge and evolve in the context of a complex metabolic, trophic and immunological crosstalk with cells of different types, including (but not limited to) epithelial, endothelial, stromal and immune cells [1, 2]. Thus, the microenvironment of solid malignancies exhibit a considerable degree of heterogeneity, not only across different types of disease, but also across the same tumor type in different patients or even different malignant lesions in the same individual [3]. Not surprisingly, both non-immunological and immunological components of the tumor microenvironment (TME) have been attributed robust prognostic and/or predictive value in multiple cohorts of patients with cancer [4–8]. In particular, high levels of tumor-infiltrating CD8+ T lymphocytes (CTLs), which are key mediators of anticancer immunity, are strongly associated with prolonged survival in patients affected by various solid tumors including high-grade serous ovarian carcinoma (HGSC) [9–12]. Intriguingly, the majority of HGSCs containing high frequencies of CD8+ CTLs are also robustly infiltrated by CD20+ B cells [13], and patients whose tumors exhibit such an abundant co-infiltration have higher survival rates than patients with tumors that only contain high amounts of CD8+ CTLs [14, 15]. That said, the cellular mechanisms that govern the recruitment of CD8+ CTLs and CD20+ B cells to the microenvironment of HGSCs and their activation remain unclear.

It has previously been shown that CD8+ and CD20+ cells often co-localize in lymphoid aggregates of different
sizes and morphologies in the HGSC microenvironment [15]. These aggregates, which have previously been identified as tertiary lymphoid structures (TLSs), are known for their ability to initiate tumor-targeting immunity and for their positive prognostic value in patients with various tumor types [16–19]. TLSs harbor indeed prominent B-cell follicles adjacent to discrete zones containing CD4+ and CD8+ T cells, dendritic cells (DCs) and high endothelial venules [18, 20]. Since mature DCs selectively home to TLS, they constitute a reliable and specific marker of these structures [21, 22]. Nevertheless, the impact of mature DCs on the composition and functional orientation of the tumor infiltrate, their ability to drive T cell-dependent anticancer immunity, and their potential prognostic and predictive value in the setting of HGSC remain to be deciphered.

Here, we investigated the clinical impact of tumor infiltration by mature DCs in three independent cohorts of 81, 66 and 20 patients with resectable HGSC who did not received neoadjuvant chemotherapy. Our data suggest that while both mature DC-LAMP+ Dcs and CD20+ B cells participate in the generation of anticancer immunity, only the former are critical for licensing a CTL-dependent tumor-targeting immune response that translates into clinical benefit for HGSC patients.

Materials and methods

Patients

Study groups 1 and 2. Two retrospective series of 81 and 66 formalin-fixed paraffin-embedded (PPFE) samples were obtained from patients with HGSC who underwent primary surgery in the absence of neoadjuvant chemotherapy. Our data suggest that while both mature DC-LAMP+ DCs and CD20+ B cells participate in the generation of anticancer immunity, only the former are critical for licensing a CTL-dependent tumor-targeting immune response that translates into clinical benefit for HGSC patients.

Here, we investigated the clinical impact of tumor infiltration by mature DCs in three independent cohorts of 81, 66 and 20 patients with resectable HGSC who did not received neoadjuvant chemotherapy. Our data suggest that while both mature DC-LAMP+ DCs and CD20+ B cells participate in the generation of anticancer immunity, only the former are critical for licensing a CTL-dependent tumor-targeting immune response that translates into clinical benefit for HGSC patients.

Table 1

| Table 1 Main clinical and biological characteristics of 81 HGSC patients enrolled in the study (University Hospital Hradec Kralove) |
| Variable | Overall cohort (n = 81) |
| Age | Mean age (y) ± SEM 61 ± 10 |
| Range | 31–84 |
| pTNM stage | |
| Stage I | 20 (24.5%) |
| Stage II | 6 (7.4%) |
| Stage III and IV | 55 (68.1%) |
| Debulking | |
| R0 | 38 (47.0%) |
| R1 | 11 (13.5%) |
| R2 | 32 (39.5%) |
| Vital status of patients | 39 (47.5%) |

Pathologic staging was performed according to the 8th TNM classification (2017), and histologic types were determined according to the current WHO classification [23, 24]. Data on long-term clinical outcome were obtained retrospectively by interrogation of municipality registers or the patient’s families. Study group 3. An additional series of 20 samples from HGSC patients was prospectively collected at Hospital Motol (Czech Republic) (Additional file 1: Table S5). Study group for NGS. 18 HGSC patient samples collected at Hospital Motol (Czech Republic) were used for NGS data analysis (Additional file 1: Table S6). Written informed consent was obtained from patients before inclusion in the study. The protocol was approved by the local ethics committee.

Immunohistochemistry

Tumor specimens from study groups 1 and 2 were fixed in neutral buffered 10% formalin solution and embedded in paraffin as per standard procedures. Immunostaining with antibodies specific for lysosomal associated membrane protein 3 (LAMP3; best known as DC-LAMP), CD8, CD20 and natural cytotoxicity triggering receptor 1 (NCR1; best known as Nkp46) (Additional file 1: Table S2) was performed according to conventional protocols. Briefly, tissue sections were deparaffinized, followed by antigen retrieval with Target Retrieval Solution (Leica) in EDTA pH 8 in preheated water bath (98 °C, 30 min). The sections were allowed to cool down to RT for 30 min, and endogenous peroxidase was blocked with 3% H2O2 for 15 min. Thereafter, sections were treated with protein block (DAKO) for 15 min and incubated with primary antibodies, followed by the revelation of enzymatic activity. Images were acquired using a Leica Aperio AT2 scanner (Leica).

Cell quantification

DC-LAMP+ cells were differentially quantified in the tumor stroma and tumor nests of the whole section with Calopix (Tribvn). The total number of CD8, Nkp46 and CD20 density was analyzed on the entire tumor section of all 81 HGSC patients using Calopix software without further division for tumor stroma and tumor nest based on previous published protocols [14, 22, 25]. The Nkp46 staining was performed based on previously optimized and published protocols [22, 25] and appropriate isotype controls were used throughout the study. The antibody against Nkp46/NCR1 (R&D), clone 195,314 is suitable for immunohistochemistry analysis as indicated by manufacturer. Data are reported as absolute number of positive cells/mm² (for DC-LAMP+, CD8+ Nkp46+ cells) or cell surface/total tumor section surface (for CD20+ cells), as previously described [14, 21]. TLS were enumerated in whole sections using upon assessment of co-localizing DC-LAMP+ and CD20+ B cells, as previously described.
Immunostaining and quantifications were reviewed by at least three independent observers (IT, LK, JF, PS, JL) and an expert pathologist (JL, PS).

Flow cytometry
Total live mononuclear cells were isolated from fresh tumor specimens, as previously described [26]. Mononuclear cells were stained with several panels of fluorescent primary antibodies (Additional file 1: Table S3) or appropriate isotype controls for 20 min at 4 °C in the dark, following by washing and acquisition on a Fortessa flow cytometer (BD Bioscience). Flow cytometry data were analyzed with the FlowJo software (TreeStar). Gating strategies are depicted in Additional file 1: Figure S3A and 3C.

Degranulation and IFN-γ production after in vitro stimulation
Mononuclear cells isolated from fresh tumor specimens were stimulated with 50 ng/mL phorbol 12-myristate 13-acetate (PMA) + 1 μg/mL ionomycin in the presence of anti-CD107a FITC monoclonal antibody (BioLegend) for 1 h followed by 3 h incubation with brefeldin A (BioLegend). Unstimulated cells were used as control. Cells were then washed in PBS, stained with anti-CD45 PerCP (EXBIO), anti-CD3 Alexa Fluor 700 (EXBIO) or APC-eFluor780 (eBioscience), anti-CD4 ECD (Beckman Coulter), anti-CD8 HV500 (BD Biosciences) and anti-CD56 Alexa Fluor 700 (BioLegend) monoclonal antibodies, fixed in fixation/permeabilization buffer (eBioscience), permeabilized with permeabilization buffer (eBioscience) and stained with anti-IFN-γ PE-Cy7 (eBioscience), anti-granzyme B Brilliant Violet 421 (BD Biosciences) and anti-perforin APC (BioLegend) monoclonal antibodies. The percentage of CD3⁺CD8⁺ T cells and CD3⁺CD56⁺ NK cells producing IFN-γ and degranulating upon PMA/ionomycin stimulation were determined by flow cytometry. The data were analyzed with the FlowJo software package (Tree Star, Inc.).

NGS data analysis
Hierarchical clustering analysis was conducted for differentially expressed genes (DEGs) using the PHEATMAP package in R, based on The Euclidean distance and complete clustering method. GO, KEGG and REACTOME analyses were performed using ClueGo [27]. The MCP-counter R package was used to estimate the abundance of tissue-infiltrating immune cell populations [28].

Statistical analysis
Survival analysis was performed using the Survival R package, using both log-rank tests and Cox proportional hazard regressions. For log-rank tests, the prognostic value of continuous variables was assessed using median-based cutoffs. For Cox proportional hazard regressions, immune densities were log-transformed. Variables that were not significantly associated with prognosis in univariate Cox regression (Wald test \( p > 0.05 \)), as well as variables that were intrinsically correlated, were not included in multivariate Cox regressions. Fisher's exact tests, Student's \( t \) tests, and the Wilcoxon and Mann-Whitney tests were used to assess statistical significance, \( p \) values are reported (considered not significant when \( p > 0.05 \)).

Results
Prognostic impact of mature DC infiltration in HGSC
Tumor samples from a retrospective series of 81 patients with HGSC who did not receive neoadjuvant chemotherapy (Table 1), were analyzed for the density of DC-LAMP⁺ DCs by immunohistochemistry (IHC) (Additional file 1: Figure S1A). Although density was relatively heterogeneous across samples, mature DCs were mainly localized to the tumor stroma (median = 3.66 cells/mm²) rather than in direct apposition with tumor cell nests (median = 0.42 cells/mm²) (Additional file 1: Figure S1B). To evaluate the prognostic impact of DC-LAMP⁺ cells in this patient cohort, we stratified it based on median density of DC-LAMP⁺ cells in the tumor stroma and tumor nest, followed by retrospective RFS and OS analysis. Patients with high density of DC-LAMP⁺ cells (DC-LAMP⁺) in the tumor stroma exhibited significantly longer RFS and OS as compared to their DC-LAMP⁻ counterparts (median RFS: 55 mo. versus 28 mo.; \( p < 0.0001 \); median OS; > 120 mo. versus 41 mo.; \( p = 0.0002 \)) (Table 2). We also identified a trend toward improved OS (but not RFS) for HGSC patients with a high density of DC-LAMP⁺ DCs in tumor nests (Additional file 1: Figure S1C).

Univariate Cox analysis confirmed the prognostic impact of mature DC infiltration in both the tumor stroma (\( p = 0.0008 \)) and the tumor nest (\( p = 0.018 \)) (Table 2). To validate these findings in an independent cohort, we evaluated the prognostic role of mature DCs in a group of 66 patients with HGSC who did not receive neoadjuvant chemotherapy (Additional file 1: Table S1). Also in this set of samples, DC-LAMP⁺ cells were mainly found in the tumor stroma compared to the tumor nest (data not shown). Moreover, low densities of DC-LAMP⁺ cells in the tumor stroma were also associated with an increased risk of relapse and poor prognosis in this cohort (Fig. 1c, d). Indeed, median OS was only 49 mo. for DC-LAMP⁻ patients, compared to > 120 mo. for their DC-LAMP⁺ counterparts (Fig. 1d). These results demonstrate that the presence of DC-LAMP⁺ cells in the tumor stroma constitutes a strong prognostic biomarker for the identification of HGSC patients with favorable disease outcome upon tumor resection, as confirmed by multivariate Cox analysis (Table 3).

To evaluate the density of mature DCs within TLSs as well as the prognostic impact of the latter, we quantified TLSs by examining the co-localization of DC-LAMP⁺...
DCs with CD20+ B cells. In line with previous findings [15], TLSs were only found in 10% of specimens from both cohorts of HGSC patients included in this study (data not shown). Next, we stratified patients from both cohorts based on the presence of TLSs within their TME and investigated whether TLS Neg and TLS Pos patients differed in terms of OS. The presence of TLS did not influence OS in these retrospective cohorts of HGSC patients (Additional file 1: Figure S2, Table 2).

![Fig. 1](image-url)

Fig. 1 Prognostic impact of mature DCs in the tumor microenvironment of chemotherapy-naive HGSC patients. RFS (a, c) and OS (b, d) of two cohorts of 81 (a, b) and 66 (c, d) patients with HGSC who did not receive neoadjuvant chemotherapy, upon stratification based on median density of DC-LAMP+ cells in the tumor stroma. Survival curves were estimated by the Kaplan-Meier method, and differences between groups were evaluated using log-rank test. Number of patients at risk are reported.

### Table 2: Univariate Cox proportional hazard analysis

| Variable          | Overall survival |
|-------------------|------------------|
| Age               | HR (95% CI)      | p     |
| CA125             | 1.23 (0.99–1.54) | 0.058 |
| CD8               | 0.78 (0.63–0.96) | 0.022 |
| CD20              | 0.09 (0.01–0.72) | 0.023 |
| DC-LAMP stroma    | 0.53 (0.37–0.77) | 0.0008|
| DC-LAMP tumor     | 0.48 (0.27–0.88) | 0.018 |
| DC-LAMP summary   | 0.52 (0.34–0.81) | 0.0037|
| Debulking         | 1.48 (1.07–2.03) | 0.018 |
| NKp46             | 0.57 (0.25–1.42) | 0.24  |
| Stage             | 2.03 (1.34–3.07) | 0.0008|

DCs with CD20+ B cells. In line with previous findings [15], TLSs were only found in 10% of specimens from both cohorts of HGSC patients included in this study (data not shown). Next, we stratified patients from both cohorts based on the presence of TLSs within their TME and investigated whether TLS Neg and TLS Pos patients differed in terms of OS. The presence of TLS did not influence OS in these retrospective cohorts of HGSC patients (Additional file 1: Figure S2, Table 2).

### Table 3: Multivariate Cox proportional hazard analysis

| Variable          | Overall survival |
|-------------------|------------------|
| Stage             | HR (95% CI)      | p     |
| DC-LAMP stroma    | 0.62 (0.44–0.87) | 0.0057|
Mature DCs correlate with signs of a T_{H}1-polarized effector immune response

To characterize the impact of mature DCs on the composition of the HGSC immune infiltrate, we used RNA-Seq to compare gene expression profiles of 9 DC-LAMP^{Hi} and 9 DC-LAMP^{Lo} patients, as identified by IHC (Additional file 1: Table S6). We identified a set of 199 genes that were significantly overrepresented in from DC-LAMP^{Hi} patients as compared to their DC-LAMP^{Lo} counterparts (Fig. 2a; Additional file 1: Table S4). Functional studies revealed a strong association between DEGs with immune system activation and inflammation. Alongside, we used the MCP-counter R package to estimate the relative abundance of different cell populations in the TME of DC-LAMP^{Hi} versus DC-LAMP^{Lo} patients. Thus, compared to their DC-LAMP^{Lo} counterparts, DC-LAMP^{Hi} tumors exhibited overrepresentation of sets for genes specific of T cells \((p = 0.0003)\), CD8^{+} T cells \((p = 0.01)\), cytotoxic lymphocytes \((p = 0.0006)\) and NK cells \((p = 0.017)\) (Fig. 2b). To extend these findings to other genes potentially involved in the activity of distinct immune cell subsets, we included known markers of subpopulations of T cells, CD8^{+} T cells, helper T cells, NK cells and B cells (Fig. 2c). Compared to their DC-LAMP^{Lo} counterparts, DC-LAMP^{Hi} tumors exhibited an overrepresentation of gene sets specifically clustering to the following immunological functions: T cells, CD8 cytotoxicity, T_{H}1 polarization, T cell activation, NK cells and plasma cells (Fig. 2c). The expression of genes related to T_{H}1 polarization, T cell phenotype and B cells did not differ between DC-LAMP^{Hi} and DC-LAMP^{Lo} samples (Fig. 2c). We next validated these findings by assessing the expression levels of the most significant DEGs in a large group of HGSC patients \((n = 46)\). Confirming RNA-Seq data, C-C motif chemokine ligand 5 (CCL5), C-C motif chemokine receptor 4 \((CCR4)\), CD3, CD4, CD40, CD40 ligand \((CD40L)\), CD8A, cytokotic T-lymphocyte associated protein 4 \((CTLA4)\), granzyme A \((GZMA)\), granzyme B \((GZMB)\), IL18 and perforin 1 \((PRF1)\) were all significantly overrepresented in DC-LAMP^{Hi} HGSCs as compared to their DC-LAMP^{Lo} counterparts (Fig. 2d). Altogether, these results demonstrate that an abundant infiltration by mature DCs correlates with an immune contexture characterized by T_{H}1 polarization, infiltration by effector cells \((T \text{ cells, NK cells and plasma cells})\) and cytotoxic effector functions.

Mature DCs are associated with HGSC infiltration by IFN-γ-producing CD8^{+} T cells

A correlation between robust tumor infiltration by CD8^{+} T cells and an elevated intratumoral frequency of mature DCs has previously been reported for many types of human cancers \([21, 22, 29]\). As we observed a positive correlation between DC-LAMP^{+} DC density and the levels of several transcripts associated with CD8^{+} T cell responses, we further evaluated CD8^{+} T cell infiltrate in HGSC samples by IHC (Fig. 3a). We observed a higher density of CD8^{+} T cells in DC-LAMP^{Hi} HGSCs as compared to their DC-LAMP^{Lo} counterparts \((p = 0.001\) and \(p = 0.0001\), respectively) (Fig. 3b), corroborating the notion that DC-LAMP^{Lo} lesions have a less abundant infiltrate than DC-LAMP^{Hi} tumors. To address the functional capacity of CD8^{+} T cells found in the HGSC TME, we employed flow cytometry on tumors freshly resected from a prospective cohort of 20 HGSC patients (Additional file 1: Table S5), which were also analyzed for DC-LAMP^{+} cell density by IHC. In line with our previous results, we observed a significantly higher percentage of CD3^{+}CD45^{+} and CD3^{+}CD8^{+} T cells amongst live mononuclear cells in DC-LAMP^{Hi} versus DC-LAMP^{Lo} HGSCs (Additional file 1: Figure S3B). Moreover, non-specific stimulation caused a more pronounced increase in CD8^{+} T cells staining positively for IFN-γ, IFN-γ/GZMB and IFN-γ/CD107a \((CD107a\) is a marker of degranulation) when CD8^{+} T cells were isolated from DC-LAMP^{Hi} versus DC-LAMP^{Lo} tumors \((p = 0.041, p = 0.027\) and \(p = 0.021\), respectively) (Fig. 3c, Additional file 1: Figure S3A). These data corroborate our previous findings showing the overrepresentation of IFNG, PRF1 and GZMB amongst 23 patients with DC-LAMP^{Hi} HGSC, compared to their 23 DC-LAMP^{Lo} counterparts by qRT-PCR (Fig. 2d). Thus, in both retrospective and prospective cohorts of patients, the presence of mature DCs correlated with increased frequencies of CD8^{+} T cells with enhanced effector functions. Confirming prior observations, high densities of CD8^{+} T cells had a positive impact on the OS of HGSC patients \((p = 0.01)\) (Fig. 3d, Table 2). Since both mature DCs and CD8^{+} T cells influence disease outcome in patients with HGSC not receiving neoadjuvant chemotherapy, we assessed OS upon stratifying patients from study group 1 into four subsets \((DC-LAMP^{Hi}/CD8^{Hi}, DC-LAMP^{Hi}/CD8^{Lo}, DC-LAMP^{Lo}/CD8^{Hi}\) and \(DC-LAMP^{Lo}/CD8^{Lo}\)\). DC-LAMP^{Hi}/CD8^{Hi} patients exhibited the best disease outcome in this setting \((\text{median OS} > 120 \text{ mo.})\), which was significantly better than OS amongst DC-LAMP^{Lo}/CD8^{Hi} patients \((\text{median OS:} 50 \text{ mo.}, p = 0.0004)\) (Fig. 3e). Intriguingly, DC-LAMP^{Lo}/CD8^{Hi} patients had an even poorer median OS \((18 \text{ mo.})\) (Fig. 3e). However, the size of this specific patient group was too small to enable a statistical assessment of this observation.

Mature DCs are associated with HGSC infiltration by cytotoxic NK cells

Both the innate and adaptive arm of the immune system contribute to cancer immunosurveillance \([30]\). Thus, driven by the positive correlation between the density of mature DCs in the HGSC TME and the abundance of NK cell-related transcripts, we next evaluated the
**Fig. 2** (See legend on next page.)
association between DC-LAMP+ DCs and NK cells by IHC (based on the specific NK cell marker NKp46) [31]. NK cells were mainly localized to tumor invasive margin and stroma, were rarely in contact with malignant cells, and were generally found outside of TLIs (Fig. 3f). We observed a higher density of NK cells in the tumor stroma (but not in tumor nests) in DC-LAMPHi versus DC-LAMPLo samples (Fig. 3g), corroborating RNA-Seq data (Fig. 2c). To obtain insights into the functional capacity of NK cells infiltrating the TME, we used flow cytometry on freshly resected samples from a prospective cohort of 20 patients with HGSC (Additional file 1: Table S5), which were also analyzed for DC-LAMP+ cell density by IHC (Additional file 1: Figure S3C). We next compared the expression of 15 NK cell markers amongst CD3+CD56+ NK cells isolated from freshly resected DC-LAMPHi or DC-LAMPLo HGSCs. Although NK cell receptors were not differentially expressed in these two groups of samples (data not shown), non-specific stimulation was much more effective at inducing the acquisition of effector functions amongst NK cells from DC-LAMPHi patients (versus their DC-LAMPLo counterparts), as assessed by the percentage of NK cells expressing IFN-γ, IFN-γ/GZMB and IFN-γ/PRF1 (p = 0.046, p = 0.036 and p = 0.042, respectively) (Fig. 3h). These results suggest that intratumoral NK cells from DC-LAMPLo patients display an impaired capacity to acquire effector functions, even though their surface phenotype is unaltered.

Although NK cells have been associated with improved disease outcome in patients with some solid tumors [22], their prognostic impact on HGSC is unknown. We therefore stratified HGSC patients based on median NKp46+ cell density in the TME, finding no significant differences in OS between these two groups (Additional file 1: Figure S3D, Table 2). Importantly, when we stratified patients into four groups based on both DC-LAMP+ cell density and NKp46+ NK cell density, we observed that DC-LAMPHi/NKp46Hi patients had superior disease outcome (median OS > 120 mo.) as compared to DC-LAMPl0/NKp46Lo patients (median OS 26.5 mo.; p = 0.0005) (Fig. 3i).

**CD20+ B cells in the HGSC TME correlate with mature DCs and long-term survival**

B cell density strongly correlates with CD8+ T cell infiltration and favorable disease outcome in patients with HGSC [13]. Nevertheless, the association between CD20+ cells and mature DCs, as well as their impact on the immune contexture of HGSC remain unknown. Tumor-infiltrating CD20+ B cells were found in >50% of patients with HGSC by IHC (data not shown), exhibiting a robust positive correlation with DC-LAMP+ DC density, in both the tumor stroma and tumor nests (p = 0.0001 and p = 0.0004, respectively) (Fig. 4a, b). These results are in line with our previous findings showing that a high density of DC-LAMP+ cells in the TME is associated with the overrepresentation of a plasma cell gene signature (Fig. 2c).

Next, we divided our entire patient cohort into 4 groups according to the density of mature DCs and CD20+ B cells (DC-LAMPl0/CD20Lo, DC-LAMPLo/CD20Hi, DC-LAMPHi/CD20Lo, DC-LAMPHi/CD20Hi), with the specific aim to assess CD8+ T cell infiltration. Interestingly, we observed a significantly higher density of CD8+ T cells in DC-LAMPHi/CD20Hi patients as compared to all other groups. Moreover, DC-LAMPHi/CD20Lo samples exhibited a significantly higher density of CD8+ T cells than DC-LAMPl0/CD20Lo group (Fig. 4c). By combining IHC and biomolecular analyses, we demonstrated that CCR4, CXCL14, CCR7, CCL5, CCR2, CCL19, CCL22, CCR1, CCL18, CCR2L2, CXC3, CCR10, CCR5 and CXCL9 are overrepresented in DC-LAMPHi/CD20Hi samples as compared to their DC-LAMPl0/CD20Lo counterparts (Fig. 4d).

Functional analyses revealed that all these DEGs are mainly involved in lymphocyte, DC and monocyte chemotaxis (Additional file 1: Figure S4). Finally, by combining IHC and flow cytometry, we detected a significantly higher percentage of IFN-γ+ and PRF1+ cells amongst CD8+ T cells from DC-LAMPHi/CD20Lo tumors compared to their DC-LAMPl0/CD20Lo counterparts (Fig. 4e).

Confirming prior observations [15], robust tumor infiltration by CD20+ B cells had a positive impact on the survival of patients with HGSC (p = 0.018) (Fig. 4f, Table 2). Importantly, high levels of both CD8+ CTLs and CD20+ B cells were associated with most favorable clinical outcome.
Fig. 3 (See legend on next page.)
amongst the patients involved in this study ($p = 0.049$) (Fig. 4g). Indeed, median survival for CD8$^{Hi}$/CD20$^{Hi}$ patients was > 120 mo., where it was only 47 mo. for CD8$^{Lo}$/CD20$^{Lo}$ patients ($p = 0.0004$). These findings are in accordance with the results from survival analysis showing that DC-LAMP$^{Hi}$ patients have the best OS irrespective of CD20$^+$ B cell density (Fig. 4h). Altogether, our data suggest that while both mature DC-LAMP$^+$ DCs and CD20$^+$ B cells shape the immune contexture of HGSCs, only the former are critical for enabling a clinically relevant anticancer response driven by CD8$^+$ CTLs.

Finally, we evaluated the combined prognostic value of DC-LAMP$^+$, CD8$^+$ and CD20$^+$ cell density by stratifying our cohort in three groups of patients: DC-LAMP$^{Hi}$/CD8$^{Hi}$/CD20$^{Hi}$ patients, DC-LAMP$^{Lo}$/CD8$^{Lo}$/CD20$^{Lo}$ patients, and patients in which either of the three parameters was discordant with the remaining two (which we named DC-LAMP/CD8/CD20Mix). DC-LAMP$^{Hi}$/CD8$^{Hi}$/CD20$^{Hi}$ patients had superior RFS (not shown) and OS (median > 120 mo.) compared with their DC-LAMP$^{Lo}$/CD8$^{Lo}$/CD20$^{Lo}$ counterparts (median OS: 47 mo.) as well as DC-LAMP/CD8/CD20Mix patients (median OS 40 mo.) (Fig. 4i). Taken together, these findings indicate that the concomitant assessment of DC-LAMP$^+$ DCs, CD20$^+$ B cells and CD8$^+$ CTLs in the TME of patients with HGSC conveys robust prognostic information.

**Discussion**

The composition of the immune infiltrate in human solid tumors, its localization and functional orientation are major predictors of patient survival, as previously documented [5, 32]. In particular, high densities of intratumoral CD8$^+$ CTLs and CD20$^+$ B cells have been associated with improved clinical outcome in patients affected by a variety of tumors, including HGSC [13, 21]. Elevated intratumoral levels of DC-LAMP$^+$ DCs also constitute a robust positive prognostic value in multiple oncological settings, including non-small-cell lung carcinoma (NSCLC) [14, 21, 33], melanoma [34], renal cell carcinoma (RCC) [29], breast cancer [35] and colorectal carcinoma (CRC) [22]. Nevertheless, the impact of DC-LAMP$^+$ cells on the composition and functional orientation of the immune contexture of HGSC and its prognostic role remained to be elucidated. Here, we assessed the prognostic value of DC-LAMP$^+$ cell densities in two independent retrospective cohorts of patients with HGSC who did not receive neoadjuvant chemotherapy ($n = 81$ and $n = 66$).

We observed a major inter-individual variability in DC-LAMP$^+$ cell densities. The great majority of mature DCs were localized in the tumor stroma and associated with TLSs (rather than being in direct contact with malignant cell nests), as previously observed in samples from NSCLC, RCC and CRC [14, 21, 22, 29]. In NSCLCs, mature DCs provide a specific marker for TLSs and constitute a favorable prognostic biomarker for survival [21, 33]. TLSs were identified only in 19% of our HGSC samples, which is in line with previous findings, and their abundance did not correlate with OS [15]. We therefore decided to evaluate the prognostic impact of DC-LAMP$^+$ DCs in the entire tumor stroma and tumor nest. High densities of mature DCs in the TME were strongly associated with improved RFS and, most importantly, superior OS in both independent retrospective cohorts.

By combining IHC and biomolecular analyses, we demonstrated that a high density of tumor-infiltrating mature DCs is associated with a T$_{H}1$-polarized immune contexture that acquired effector functions. These results recapitulate previous findings in the setting of NSCLC [21, 33] and CRC [22, 36]. The presence of tumor-infiltrating CD8$^+$ CTLs is strongly associated with improved clinical outcome amongst patients with HGSC [9, 12, 13]. Accordingly, we found a strong correlation between CD8$^+$ CTL density and improved OS in our cohorts of HGSC patients. In both prospective and retrospective studies, we showed that CD8$^+$ T cells co-localize preferentially with mature DCs in the HGSC TME, and that the density of CD8$^+$ T cells is profoundly diminished in DC-LAMP$^{Lo}$ tumors. DC-LAMP$^{Hi}$ patients with a concomitantly elevated density of CD8$^+$ CTLs in their tumors had a significant clinical benefit as compared to patients with low intratumoral levels of both
Fig. 4 Impact of mature DCs and CD20+ B cells on the immune contexture of HGSCs and associated anticancer immune response. 

a Representative images of DC-LAMP immunostaining. Scale bar = 50 μm. 

b Density of CD20+ B cells in the tumor stroma and tumor nest in DC-LAMPLo versus DC-LAMPHi HGSCs (n = 81). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum.

c Density of CD8+ T cells in DC-LAMPLo/CD20Lo, DC-LAMPHi/CD20Lo, DC-LAMPHi/CD20Hi, DC-LAMPHi/CD20Hi HGSCs. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum.

d Relative expression levels of CCR4, CXCL14, CCR7, CCL5, CCR2, CCL19, CCL22, CCR1, CCL18, CCR2, CCR10, CCR5, and CXCL9 in 9 DC-LAMPHi/CD20Hi versus 9 DC-LAMPLo/CD20Lo HGSCs, as determined by RNA-Seq and IHC. Benjamin-Hochberg correction was used for RNA-Seq data.

e Percentage of IFN-γ+ and PRF1+ cells among CD8+CD3+ T cells from 10 DC-LAMP Lo and 10 DC-LAMPHi samples. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum.

f, g, h, i OS of HGSC patients who did not receive neoadjuvant chemotherapy, upon stratification based on median density of CD20+ cells plus CD8+ cells (g), CD20+ cells plus DC-LAMP+ cells (h), or median density of all 3 parameters (i). Survival curves were estimated by the Kaplan-Meier method, and differences between groups were evaluated using log-rank test. Number of patients at risk are reported.
mature DCs and CD8+ CTLs. Moreover, DC-LAMPLo/CD8Hi patients had significantly worse disease outcome than their DC-LAMPHi/CD8Hi counterparts. Thus, DC-LAMP stands out as a robust biomarker allowing for the identification of CD8+ HGSC patients with higher risk of death.

In contrast to the well-established antitumor activity of CD8+ CTLs, there is little evidence in support of a similar function from NK cells (in the setting of HGSC) [37]. NKP46+ NK cells were mainly localized at invasive tumor margins and within the stroma of HGSC samples, which is in line with previous finding in the NSCLC, CRC and RCC setting [22, 25]. Importantly, increased intratumoral levels of NK cells have been associated with good prognosis in patients with RCC, although a similar prognostic value could not be documented in NSCLC and CRC [22, 25]. Along similar lines, the density of NK cells did not influence clinical outcome in our cohorts of HGSC patients. Although the cell surface properties of NK cells did not differ between DC-LAMPHi and DC-LAMPLo samples, we observed significantly a higher frequency of IFN-γ+/PRF1+ and IFN-γ+/GZMB+ NK cells after non-specific stimulation in the former. Finally, in line with previous observations on CRC, DC-LAMPHi patients with concomitantly elevated amounts of intratumoral NK cells had a significant clinical benefit compared with DC-LAMPLo/NKP46Lo individuals [22].

Taken together, our data demonstrate that robust tumor infiltration by mature DCs generates an immune contexture characterized by T11 polarization and cytotoxic functions.

Importantly, the presence of CD20+ B cells correlates with improved OS in our cohorts of chemotherapy-naïve patients with HGSC, which is line with previous observations from other oncological settings [13, 14, 38–41]. Notably, HGSCs containing elevated amounts of both CD8+ CTLs and CD20+ B cells are associated with superior survival than HGSCs containing high levels of either CD8+ CTLs or CD20+ B cells [13]. These findings suggest not only the existence of cooperative interactions between CD8+ CTLs and CD20+ B cells in the TME of HGSCs, but also the critical role of B cells in regulation of the immune infiltrate, as previously reported in a variety of other cancers [42, 43]. CD8+ CTLs and CD20+ B cells often co-localize in lymphoid aggregates of various sizes and morphology in HGSC samples, as previously described in detail [15]. In all such aggregates, especially in TLSs, B cells form follicles adjacent to discrete zones containing not only CD4+ and CD8+ T cells, but also high densities of DCs [18]. Accordingly, we identified a robust correlation between the presence of DC-LAMP+ DCs and CD20+ B cells in the TME of HGSC lesions.

In conclusion, by combining IHC and biomolecular analyses, we comprehensively documented for the first time the influence of both mature DCs and CD20+ B cells on the establishment of the immune contexture of HGSC. That said, DCs stand out as the critical attribute for the initiation of an immune response to HGSC which exhibits T11 polarization, is armed with immune effectors, and mediates clinical benefits. These findings are in line with previous studies documenting the critical role of mature DCs in the activation of antitumor immunity [44, 45]. Accordingly, we identified tumor infiltration by DC-LAMP+ DCs as a robust, positive prognostic biomarker for HGSC patients, as confirmed by both univariate and multivariate analyses.

### Additional file

#### Additional file 1: Figure S1. Density of mature DCs in the tumor stroma and malignant cell nest of patients with HGSCs.

(A) Representative images of DC-LAMP immunostaining (in brown) and CD20 immunostaining (in red) are shown. Scale bar = 50 μm. (B) Density of DC-LAMP+ cells in the tumor stroma and nest of patients with HGSCs (n = 81). (C) RFS and OS of 81 patients with HGSC who did not receive neoadjuvant chemotherapy, upon stratification based on median density of DC-LAMP+ cells in the tumor nest. Figure S2. Prognostic impact of tertiary lymphoid structures in HGSC patients. OS of 147 patients with HGSC who did not receive neoadjuvant chemotherapy, upon stratification based on presence or absence of TLSs. Figure S3. Evaluation of the functional profile of CD8+ T cells and NK cells from DC-LAMPHi versus DC-LAMPLo HGSC samples. (A) Gating strategy for CD8+ T cells. The percentage of cells in each gate is reported. (B) Percentage of CD45+CD3+ and CD3+CD8+ cells from freshly resected DC-LAMPHi (n = 10) and DC-LAMPLo (n = 10) HGSCs. Boxplots: lower quartile, median, upper quartile; whiskers, minimum, maximum. (C) Gating strategy for NK cells. The percentage of cells in each gate is reported. (D) OS of 81 patients with HGSC who did not receive neoadjuvant chemotherapy, upon stratification based on median NK cell density. Figure S4. ClueGo analysis of genes overrepresented in DC-LAMP+CD20+ versus DC-LAMPHi/CD20- HGSCs. Table S1. Main clinical and biological characteristics of 66 HGSC patients enrolled in the validation cohort (University Hospital Motol). Table S2. The list of antibodies used for IHC staining. The list of antibodies used for flow cytometry. Table S3. List of genes significantly overrepresented in DC-LAMPHi versus DC-LAMPLo HGSC samples as per RNA-Seq. Table S4. Main clinical and biological characteristics of 20 HGSC patients in which the freshly resected tumors were analyzed using flow cytometry (University Hospital Motol). Table S5. Main clinical and biological characteristics of 18 HGSC patients whose tumor samples were used for NGS data analysis (University Hospital Motol). (PDF 785 kb)

### Acknowledgements

Not applicable.

### Funding

This study was supported by the program PROGRES Q40/11 and PROGRES 28 (Oncology), by the project BBMHR-CZ LM20150589 and by the European Regional Development Fund-Project BBMRI-CZ: Biobank network—a versatile platform for research on the etiopathogenesis of diseases, No: IFT16013/0001674. LG is supported by startup grant from the Department of Radiation Oncology at Weill Cornell Medicine (New York, US) and by donations from Phosphatin Therapeutics (New York, US), Sotio a.s. (Prague, Czech Republic) and the Luke Heller TECPR2 Foundation (Boston, US).

### Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

### Authors’ contributions

Concept and design: PS, JL, AR, RS, JF; development of the methodology: IT, LX, MH, JF; acquisition of the data: IT, LK, LB, MH, ES, JF; analysis and

---

Truxova et al. Journal for ImmunoTherapy of Cancer (2018) 6:139 Page 11 of 13
interpretation of the data: IT, LK, MH, LP, JP, MH, TB, LR, RK, JG, JF; preparation, review, and/or revision of the manuscript and figures: IT, LK, MH, PS, JL, CSF, WHF, AR, LG, RS, JF; study supervision: RS, JF. All authors read and approved the final manuscript.

Authors’ information
Not applicable.

Ethics approval and consent to participate
The study was approved by the ethics committees at the University Hospital Motol and University Hospital Hradec Kralove in accordance with Czech law.

Consent for publication
Not applicable.

Competing interests
LG provides remunered consulting to OmniSEQ (Buffalo, NY, USA), Astra Zeneca (Gaithersburg, MD, USA), VL47 (New York, NY, USA) and the Luke Heller TECPR2 Foundation (Boston, MA, USA). All other authors have no financial interests to disclose.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. 2Sorbonne Université, Paris, France. 3Department of Pathology and Molecular Medicine, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. 4The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. 5Department of Gynecology and Obstetrics, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. 6Department of Gynecology and Obstetrics, Charles University, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic. 7Department of Gynecology and Obstetrics, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. 8INSERM, U1138, Centre de Recherche des Cordeliers, Paris, France. 9Sorbonne Université, Paris, France. 10Université Paris Descartes/Paris V, Paris, France. 11Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. 12Sandra and Edward Meyer Cancer Center, New York, NY, USA.

Received: 26 October 2018 Accepted: 8 November 2018

Published online: 04 December 2018

References
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
2. Rybstein MD, Bravo-San Pedro JM, Kroemer G, Galluzzi L. The autophagic network and cancer. Nat Cell Biol. 2018;20:243–51.
3. Maley CC, Altipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, et al. Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer. 2017;17:605–19.
4. Becht E, Giraldo NA, Dieu-Noyscean MC, Sautes-Fridman C, Fridman WH. Cancer immune contexture and immunotherapy. Curr Opin Immunol. 2016;39:7–13.
5. Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717–34.
6. Fucikova J, Moserova I, Urbanova I, Bozu L, Kepp O, Cremer I, et al. Prognostic and predictive value of DAMPs and DAMP-associated processes in Cancer. Front Immunol. 2015;6:402.
7. Senovilla L, Vecchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoclinmimology. 2012;1:1233–43.
8. Turajic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JL, et al. Tracking Cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell. 2018;173:581–94 e12.
9. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124:192–8.
10. Chen DS, Milliman L. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–30.
11. Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228–41.
12. Zhang L, Conejo-Garcia JR, Katsanos D, Gimmott PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.
13. Nielsen JS, Sahota RA, Milne K, Kost SE, Nestlinger NJ, Watson PH, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012;18:3281–92.
14. Germain C, Gnjatic S, Tamzali F, Knockaert S, Remm R, Goc J, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Ann J Respir Crit Care Med. 2014;189:892–4.
15. Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, Cytoytic T-cell responses, and superior prognosis in ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22:3005–15.
16. Di Caro G, Bergomos F, Grizzi F, Doni A, Bianchi P, Malces A, et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20:2147–58.
17. Lee HK, Park IA, Song IH, Shin SJ, Kim JY, Yu JH, et al. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J Clin Pathol. 2016;69:422–30.
18. Sautes-Fridman C, Lawand M, Giraldo NA, Kaplon H, German C, Fridman WH, et al. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol. 2016;7:407.
19. Wissing AM, Rikardsen OG, Steigen SE, Uhlin-Hansen L, Hadler-Olsen E. Characterisation and prognostic value of tertiary lymphoid structures in oral squamous cell carcinoma. BMC Clin Pathol. 2014;14:38.
20. de Chaisemartin L, Goc J, Darmotte D, Valdrié P, Magdeleinat P, Alfiano M, et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 2011;71:6391–9.
21. Goc J, Germain C, Vo-Bourjais TK, Lupo A, Klein C, Knockaert S, et al. The role of dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytokotic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2014;74:705–15.
22. Remarck R, Alfiano M, Cremer I, Lupo A, Dieu-Noyscean MC, Riquet M, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Cancer Res. 2013;73:4070–9.
23. Meinhold-Heerlein I, Fotopoulou I, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. Prognostic relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Gynecol Oncol. 2012;11:514–26.
24. O’Sullivan B, Brierley J, Byrd D, Bosman F, Kehoe S, Kossay C, et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. The Lancet Oncology. 2017;18:595–610.
25. Platonova S, Cheffils-Vicini J, Darmotte C, Crozet L, Veillard V, Valdrié P, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung cancer. Cancer Res. 2011;71:5412–22.
26. Fialova A, Partlova S, Sojka L, Hromadkova H, Brtnicky T, Fucikova J, et al. Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th1 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer. 2013;132:1070–9.
27. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091–3.
28. Becht E, Girald NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al.
Estimating the population abundance of tissue-infiltrating immune and
stromal cell populations using gene expression. Genome Biol. 2016;17:218.
29. Girald NA, Becht E, Pages F, Skliris G, Verkarre V, Vano Y, et al.
Orchestration and prognostic significance of immune checkpoints in the
microenvironment of primary and metastatic renal cell cancer. Clinical
cancer research : an official journal of the American Association for Cancer
Research. 2015;21:3031–40.
30. Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-
induced immunosurveillance in breast cancer. Nat Med. 2015;21:1128–38.
31. Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK
cells. Cancer Cell. 2017;32:135–54.
32. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and
adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–71.
33. Dieu-Nojean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al.
Long-term survival for patients with non-small-cell lung cancer with
intratumoral lymphoid structures. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology. 2008;26:4410–7.
34. Ladanyi A, Kiss J, Somlai B, Glide K, Fejos Z, Mohos A, et al. Density of
DC-LAMP(+) mature dendritic cells in combination with activated T
lymphocytes infiltrating primary cutaneous melanoma is a strong
independent prognostic factor. Cancer immunology, immunotherapy : CII.
2007;56:1459–69.
35. Martinet L, Filleron T, Le Guellec S, Rochaix P, Garrido I, Girard JP. High
endothelial venule blood vessels for tumor-infiltrating lymphocytes are
associated with lymphotoxin beta-producing dendritic cells in human
breast cancer. J Immunol. 2013;191:2001–8.
36. Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, et al. Unique
ectopic lymph node-like structures present in human primary colorectal
carcinoma are identified by immune gene array profiling. Am J Pathol.
2011;179:37–45.
37. Carlsten M, Norell H, Bryceyon YT, Poschle K, Schedvin K, Ljunggren HG, et
al. Primary human tumor cells expressing CD155 impair tumor targeting by
down-regulating DNAM-1 on NK cells. J Immunol. 2009;183:4921–30.
38. Ladanyi A, Kiss J, Mohos A, Somlai B, Lisdlay G, Glide K, et al. Prognostic
impact of B-cell density in cutaneous melanoma. Cancer immunology,
immunotherapy : CII. 2011;60:1729–38.
39. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The
prognostic significance of B lymphocytes in invasive carcinoma of the
breast. Breast Cancer Res Treat. 2012;132:545–53.
40. Milne K, Kobel M, Kolbinger SE, Barnes RO, Gao D, Gilks CB, et al. Systematic
analysis of immune infiltrates in high-grade serous ovarian cancer reveals
CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009;4:e6412.
41. Schmidt M, Bohm D, von Tome C, Steiner E, Puhl A, Pichl H, et al. The
humoral immune system has a key prognostic impact in node-negative
breast cancer. Cancer Res. 2008;68:5405–13.
42. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, et al.
Human solid tumors contain high endothelial venules: association with T-and
B-lymphocyte infiltration and favorable prognosis in breast cancer.
Cancer Res. 2011;71:5678–87.
43. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J
Immunol. 2010;185:4977–82.
44. Senovilla L, Aranda F, Galluzzi L, Kroemer G. Impact of myeloid cells on the
efficacy of anticancer chemotherapy. Curr Opin Immunol. 2014;30:24–31.
45. Steinman RM. Decisions about dendritic cells: past, present, and future.
Annu Rev Immunol. 2012;30:1–22.